Sumsuzzman D M, Wang Z, Langley JM, Moghadas SM, Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: A systematic review and meta-analysis, The Lancet Child & Adolescent Health 2025, 9: 393-403.
Du Z, Pandey A, Moghadas SM, Bai Y, Wang L, Matrajt L, Singer BH, Galvani AP, Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults, Nature Medicine 2025, 31(2): 647-652.
Moghadas SM, Shoukat A, Bawden CE, Langley JM, Singer BH, Fitzpatrick MC, Galvani AP. Cost-effectiveness of prefusion F protein-based vaccines against respiratory syncytial virus disease for older adults in the United States. Clinical Infectious Diseases. 2024, 78(5): 1328-1335.
Shoukat A, Abdollahi E, Galvani AP, Halperin SA, Langley JM, Moghadas SM, Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of respiratory syncytial virus disease among infants in Canada: A simulation study, The Lancet Regional Health - Americas 2023, 28: 100629.
Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, Galvani AP, The implications of silent transmission for the control of COVID-19 outbreaks, Proceedings of the National Academy of Sciences USA 2020, 117(30): 17513–17515.
For citation of our published studies, visit Google Scholar
John-Baptiste A, Moulin M, Li Z, Hamilton D, Crichlow G, Eisenkraft Klein D, Alemu FW, Ghattas L, McDonald K, Asaria M, Sharpe C, Pandya E, Moqueet N, Champredon D, Moghadas SM, Cooper L, Pinto A, Stranges S, Haworth-Brockman MJ, Galvani AP, Ali S, Do COVID-19 infectious disease models incorporate the social determinants of health? A systematic review, Public Health Reviews 2024, 45: 1607057.
Ali Z, Li Z, Moqueet N, Moghadas SM, Galvani AP, Cooper LA, Stranges S, Haworth-Brockman M, Pinto AD, Asaria M, Champredon D, Hamilton D, Moulin M, John-Baptiste A. Incorporating social determinants of health in infectious disease models: a systematic review of guidelines. Medical Decision Making, 2024, 44(7): 742-755.
Wang Z, Röst G, Moghadas SM, Deviation from the recommended schedule: optimal dosing interval for a two-dose vaccination programme, Royal Society Open Science 2024, 11: 231971.
Mehrab Z, Stundal L, Venkatramanan S, Swarup S, Lewis BL, Mortveit HS, Barrett CL, Pandey A, Wells CR, Galvani AP, Singer BH, Moghadas SM, Leblang D, Colwell RR, Marathe MV, A generalizable theory-driven agent-based framework to study conflict-induced forced migration. In Proceedings of the AAAI Conference on Artificial Intelligence 2024, 38: 23027-23033.
Nunes MC, Thommes E, Fröhlich H, Flahault A, Arino J, Baguelin M, Biggerstaff M, Bizel-Bizellot G, Borchering R, Cacciapaglia G, Cauchemez S, Barbier A, Claussen C, Choirat C, Cojocaru M, Commaille-Chapus C, Hon C, Kong J, Lambert N, Lauer KB, Lehr T, Mahe C, Marechal V, Mebarki A, Moghadas SM, Niehus R, Opatowski L, Parino F, Pruvost G, Schuppert A, Thiébaut R, Thomas-Bachli A, Viboud C, Wu J, Crépey P, Coudeville L,Redefining pandemic preparedness: Multidisciplinary insights from the CERP modelling workshop in infectious diseases, workshop report, Infectious Disease Modelling 2024, 9: 501-518.
Wells CR, Pandey A, Moghadas SM, Fitzpatrick MC, Singer BH, Galvani AP, Evaluation of strategies for transitioning to annual SARS-CoV-2 vaccination campaigns in the United States, Annals of Internal Medicine 2024, 177: 609-617.
Röst G, Wang Z, Moghadas SM, Waiting for the perfect vaccine, Trends in Biomathematics: Exploring Epidemics, Eco-Epidemiological Systems, and Optimal Control Strategies – Springer 2024: 217-232.
Shoukat A, Bawden CE, Röst G, LeBlanc JJ, Galvani AP, Langley JM, Moghadas SM, Impact and cost-Effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study, Vaccine 2024, 7: 1768-1776.
Moghadas SM, Shoukat A, Bawden CE, Langley JM, Singer BH, Fitzpatrick MC, Galvani AP, Cost-effectiveness of prefusion F protein-based vaccines against respiratory syncytial virus disease for older adults in the United States, Clinical Infectious Diseases 2023: 78: 1328-1335.
Shoukat A, Abdollahi E, Galvani AP, Halperin SA, Langley JM, Moghadas SM,Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of respiratory syncytial virus disease among infants in Canada: A simulation study, The Lancet Regional Health - Americas 2023, 28: 100629.